Cargando…

High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy

SIMPLE SUMMARY: Tumor mutation burden (TMB) represents the mutational load in the tumor cell genome and serves as a surrogate marker for tumor neoantigen production and potential immunogenicity. TMB has been widely explored as a complementary or alternative biomarker for immune checkpoint inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sung, Ji-Youn, Park, Dong-Won, Lee, Seung-Hyeun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495802/ https://www.ncbi.nlm.nih.gov/pubmed/36140210 http://dx.doi.org/10.3390/biomedicines10092109

Ejemplares similares

Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy
por: Kwack, Won Gun, et al.
Publicado: (2021)

High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
por: Yoon, Byung Woo, et al.
Publicado: (2020)

Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2016)

Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma
por: Hwang, In Kyoung, et al.
Publicado: (2019)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma
por: Li, Yuan-Yuan, et al.
Publicado: (2015)

Diagnostic and Predictive Values of (18)F-FDG PET/CT Metabolic Parameters in EGFR-Mutated Advanced Lung Adenocarcinoma
por: Hong, Il Ki, et al.
Publicado: (2020)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR unusual mutation status in lung adenocarcinomas
por: Alarcão, Ana, et al.
Publicado: (2010)

Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma
por: Kim, Chi Hong, et al.
Publicado: (2015)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy
por: Kim, Minhye, et al.
Publicado: (2021)

DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
por: Berger, Alice H., et al.
Publicado: (2013)

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
por: Wang, Hao, et al.
Publicado: (2021)

Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma
por: Li, Lin, et al.
Publicado: (2023)

NCAPD2 is a novel marker for the poor prognosis of lung adenocarcinoma and is associated with immune infiltration and tumor mutational burden
por: Li, Zihao, et al.
Publicado: (2023)

Predicting EGFR Mutation in Lung Adenocarcinoma: Development and Validation of the EGFR Mutation Predictive Score (EMPS) in Bali, Indonesia
por: Njoto, Edwin Nugroho, et al.
Publicado: (2023)

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma
por: Smits, Alexander J. J., et al.
Publicado: (2012)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
por: Krawczyk, Paweł, et al.
Publicado: (2013)

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2014)

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma
por: Hakozaki, Taiki, et al.
Publicado: (2020)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
por: Nishimura, Toshihide, et al.
Publicado: (2020)

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
por: Wu, Chiao-En, et al.
Publicado: (2022)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
por: Xu, Hui, et al.
Publicado: (2020)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Cuprotosis Patterns Are Associated with Tumor Mutation Burden and Immune Landscape in Lung Adenocarcinoma
por: Liu, Tingting, et al.
Publicado: (2022)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
por: Gao, Xuejuan, et al.
Publicado: (2019)

Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang, Wenting, et al.
Publicado: (2018)

Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation
por: Kim, Eun Young, et al.
Publicado: (2019)

Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
por: Ma, Kai, et al.
Publicado: (2022)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma
por: He, Qiong, et al.
Publicado: (2020)

Coexisting EGFR and TP53 Mutations in Lung Adenocarcinoma Patients Are Associated With COMP and ITGB8 Upregulation and Poor Prognosis
por: Zheng, Chang, et al.
Publicado: (2020)

Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas
por: Liang, Zhiyong, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_j1b6aapnibh8o1np28aq3seiga